Xiaoxiang Chen, MD陈小祥 医师 执行副总裁, 临床开发和注册科学负责人 陈小祥医师在全球及区域临床研究领域已有超过20年的领导及管理经验。加入和铂医药前，陈小祥医师在德国勃林格殷格翰 (Boehringer Ingelheim) 总部任新兴市场医学负责人。 陈小祥医师在职业生涯中，成功领导团队完成20多个新药在中国的临床开发及新药注册工作，涵盖了肿瘤、自身免疫、感染、心血管、呼吸、代谢、神经精神等诸多治疗领域，包括了恩利（Etanercept）, 替加环素（Tigecyline）, 文拉法辛（Venlafaxine）， 阿法替尼（Afatinib）, 尼达尼布（Nintedanib）,达比加群（Dabigatran）, 利格列汀（Linagliptin）, 恩格列净 (Empagliflozin) 等市场重磅产品。 任职德国勃林格殷格翰新兴市场的医学负责人期间，陈医师全面管理并协调包括东南亚，中国、台湾、香港，印度，中东及非洲地区等超过80个国家和地区的医学、临床工作。并在此之前担任该公司大中华区副总裁，负责所有医学临床事务。在此之前在惠氏制药 (Wyeth) 中国公司历任注册管理、医学事务、临床研究等管理职务，直至惠氏制药亚太研发中心临床研究总监，以及慢性疼痛及抗感染新药全球研发的医学项目主管。陈医师毕业于南京医科大学。 Executive Vice President, Head of Clinical Development and Regulatory Science Dr. Chen brings to Harbour BioMed more than 20 years of leadership experience in regional and global clinical development, most recently as Boehringer Ingelheim's Vice President, Regional Medical Management for Emerging Markets. During his career, Dr. Chen has led the successful clinical development and registration into the China market of more than 20 global innovative products across multiple therapeutic areas, including etanercept, tigecycline, venlafaxine, afatinib, nintedanib, dabigatran, linagliptin and empagliflozin. In his role as Medical Lead for Emerging Markets at Boehringer Ingelheim, Dr. Chen had overall medical responsibilities, including clinical development, in more than 80 countries and regions, including China, Taiwan, Hong Kong, South Eastern Asia, India, the Middle East and Africa. Previously, he served as Boehringer Ingelheim's Vice President, Head of Medicine Development of Greater China. Prior to Boehringer Ingelheim, Dr. Chen served as Director, Clinical Research & Development Organization of Wyeth Asia Pacific, until Global Medical Monitor for chronic pain and infections. Dr. Chen received his Medical Degree from Nanjing Medical University.